Prof Sattva Neelapu speaks to ecancer at the ASH virtual 2020 congress about the ZUMA-12 study.
He outlines the interim analysis of ZUMA-12 which is a phase 2 study of axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients with high-risk large B cell lymphoma (LBCL).
Prof Neelapu explained the trial design and eligibility, before outlining the treatment regimen.
He gives details of the results and toxicity profile with regular but manageable CRS.
Read more about the study here.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.